This is absolutely huge. He talks about the long held interest in allowing applications to include RWE, but the redtape around releasing data across institutions made it impractical. As of today, his agency is effectively removing all friction points to make it easy for drug applications to include them.
NWBO couldn't have planned, expected, or asked for a better regulatory environment, while waiting for its first landmark approval.
Market Data 
Markets 
AI
